Richard Schneiderman

Title: Richard Schneiderman: Innovator in Nucleic Acid Constructs for Insulin Production

Introduction

Richard Schneiderman is a notable inventor based in Sandy Hook, CT (US). He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid constructs that facilitate the regulated production of human insulin.

Latest Patents

Schneiderman holds a patent for "Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines." This innovative patent describes unique multifunctional nucleotide expression cassettes. These cassettes comprise a nucleotide sequence encoding a human protease driven by a glucose-regulatable promoter, along with a nucleotide sequence encoding human proinsulin. The design includes alterations at the B-C and C-A junctions to permit cleavage by the human protease. Additionally, a CMV promoter drives the transcription of the nucleotide sequence encoding human proinsulin. The cassettes may also include polyadenylation sequences after each structural gene, and the nucleotide sequence encoding human proinsulin may carry an H10D variant, along with the cells transformed by these constructs.

Career Highlights

Richard Schneiderman is currently associated with Boehringer Ingelheim Pharmaceuticals, Inc., where he continues to advance his research and innovations in biotechnology. His work has the potential to significantly impact the production of insulin, which is crucial for diabetes management.

Collaborations

Some of his notable coworkers include Revati J Tatake and Randall Wilber Barton. Their collaborative efforts contribute to the ongoing advancements in the field of biotechnology.

Conclusion

Richard Schneiderman's innovative work in nucleic acid constructs exemplifies the intersection of biotechnology and medical advancements. His contributions are vital for improving insulin production methods, which can lead to better management of diabetes.